Pharmacological features of peripheral vascular beds of beagles.
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001679:Biogenic Amines / Q000494:pharmacology; D001775:Blood Circulation / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects*; D003331:Coronary Vessels / Q000187:drug effects; D004176:Dipyridamole / Q000494:pharmacology; D004285:Dogs / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur / Q000098:blood supply; D005730:Ganglionic Blockers / Q000494:pharmacology; D005731:Ganglionic Stimulants / Q000494:pharmacology; D007668:Kidney / Q000098:blood supply; D008297:Male; D008643:Mesentery / Q000098:blood supply; D009705:Nucleosides / Q000494:pharmacology; D009711:Nucleotides / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D001562:Benzimidazoles; D001679:Biogenic Amines; D005730:Ganglionic Blockers; D005731:Ganglionic Stimulants; D009705:Nucleosides; D009711:Nucleotides; D010455:Peptides; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D011343:Procaine; D010042:Ouabain; D004176:Dipyridamole; D010208:Papaverine